Advertisement

Advances in the Treatment of Psychotic Depression

  • Amber R. Thompson
  • Aekta Malhotra
  • Anthony J. RothschildEmail author
Schizophrenia and Other Psychotic Disorders (J Csernansky, Section Editor)
  • 1 Downloads
Part of the following topical collections:
  1. Topical Collection on Schizophrenia and Other Psychotic Disorders

Abstract

Purpose of review

Our aim was to update the current understanding of effective treatment strategies for major depression with psychotic features (MDPSY).

Recent findings

Most treatment guidelines recommend either the combination of an antidepressant with an antipsychotic or electroconvulsive therapy (ECT) for the treatment of an acute episode of MDPSY. The optimal maintenance treatment after a person responds to either the antidepressant/antipsychotic combination or ECT is unclear particularly as it pertains to length of time the patient needs to take the antipsychotic medication. Further investigation into possible uses of ketamine, lithium carbonate, mifepristone, minocycline, and rTMS may produce possible new treatments in the future.

Summary

Unfortunately, there is no FDA-approved treatment for MDPSY. The combination of an antidepressant and antipsychotic is significantly more effective than either antidepressant monotherapy or antipsychotic monotherapy for the acute treatment of MDPSY.

Keywords

Psychosis Depression Antidepressants Antipsychotics Lithium Electroconvulsive therapy 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Rothschild has received grant or research support from Allergan, Janssen, the National Institute of Mental Health, Takeda, Eli-Lilly (medications for a NIH-funded clinical trial), Pfizer (medications for a NIH-funded clinical trial), and the Irving S. and Betty Brudnick Endowed Chair in Psychiatry; is a consultant to GlaxoSmithKline and Sanofi-Aventis; and has received royalties for the Rothschild Scale for Antidepressant Tachyphylaxis (RSAT)®; Clinical Manual for the Diagnosis and Treatment of Psychotic Depression, American Psychiatric Press, 2009; The Evidence-Based Guide to Antipsychotic Medications, American Psychiatric Press, 2010; The Evidence-Based Guide to Antidepressant Medications, American Psychiatric Press, 2012, and Up-to-Date®.

Drs. Malhotra and Thompson report no potential conflict of interest relevant to this article.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  2. 2.
    Ohayon M, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002;159:1855–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Gournellis R, Oulis P, Howard R. Psychotic major depression in older people: a systematic review. Int J Geriatr Psychiatry. 2014;29:784–96.CrossRefGoogle Scholar
  4. 4.
    Blazer D. Epidemiology of late-life depression. In: Schneider R, Lebowitz, Friedhoff, editors. Diagnosis and treatment of depression in late life. Washington DC: American Psychiatric Press; 1994. p. 9–20.Google Scholar
  5. 5.
    Baldwin R, Jolley DJ. The prognosis of depression in old age. Br J Psychiatry. 1986;149(5):574–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991;48:1075–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis. 1984;172:521–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Gournelis R, Lykouras L. Psychotic (delusional) major depression in the elderly: a review. Curr Psychiatr Rev. 2006;2(2):235–44.CrossRefGoogle Scholar
  9. 9.
    Rothschild AJ, Winer J, Flint AJ, Mulsant BH, Whyte EM, Heo M, et al. Study of pharmacotherapy of psychotic depression (STOP-PD) collaborative study group. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008;69(8):1293–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Cassano P, Fava M, Mischoulon D. Major depressive disorder with psychosis-like symptoms among Latinos. Psychiatr Serv. 2012;63(5):482–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Schatzberg A, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149:733–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Sands J, Harrow M. Vulnerability to psychosis in unipolar major depression: is premorbid functioning involved? Am J Psychiatry. 1995;152:1009–15.PubMedCrossRefGoogle Scholar
  13. 13.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Text Revision ed; 2010.Google Scholar
  14. 14.
    Prusoff B, Weissman MM, Merikangas KR, Leckman JF, Harding PS. Psychiatric illness in relatives of probands with delusional depression. Psychopharmacol Bull. 1984;20:358–61.PubMedGoogle Scholar
  15. 15.
    Weissman M, Prusoff BA, Merikangas KR. Is delusional depression related to bipolar disorder? Am J Psychiatry. 1984;141:892–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Weissman M, Warner V, John K, Prusoff BA, Merikangas KR, Wickramaratne P, et al. Delusional depression and bipolar spectrum: evidence for a possible association from a family study of children. Neuropsychopharmacology. 1988;1:257–64.PubMedGoogle Scholar
  17. 17.
    Cramer V, Torgersen S, Kringlen E. Mood disorders and quality of life. A community study. Nord J Psychiatry. 2010;64:58–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldberg J, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J Affect Disord. 2004;81:123–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am J Psychiatry. 2003;160:574–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Rothschild AJ. Clinical manual for the diagnosis and treatment of psychotic depression. Washington, DC: American Psychiatric Press; 2009.Google Scholar
  21. 21.
    Kolshus E, Ryan KM, Blackshields G, Smyth P, Sheils O, McLoughlin DM. Peripheral blood microRNA and VEGFA mRNA changes following elctroconvulsive therapy: implications for psychotic depression. Acta Psychiatr Scand. 2017;136:594–606.PubMedCrossRefGoogle Scholar
  22. 22.
    •• Nelson J, Bickford D, Delucchi K, Fiedorowicz JG, Coryell WH. Risk of psychosis in recurrent episodes of psychotic and nonpsychotic major depressive disorder: a systematic review and meta-analysis. Am J Psychiatry. 2018;175(9):897–904 Excellent review providing supporting evidence that psychotic depression is a distinct illness.PubMedCrossRefGoogle Scholar
  23. 23.
    Leadholm A, Rothschild AJ, Nolen WA, Bech P, Munk-Jørgensen P, Ostergaard SD. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord. 2013;145:214–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Association AP. Practice guideline for the treatment of patients with major depressive disorder. 2010. http://www.psychiatryonline.com/pracGuide/PracticePDFs/PG_Depression3rdEd.pdf. 2018. Accessed 22 Jan 2019
  25. 25.
    Milev R, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. CANMAT depression work group. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatr. 2016;61(9):561–75.CrossRefGoogle Scholar
  26. 26.
    Kennedy S, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. CANMAT depression work group. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatr. 2016;61(9):540–60.CrossRefGoogle Scholar
  27. 27.
    Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ. Wfsbp task force on treatment guidelines for unipolar depressive disorders. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76–95.PubMedCrossRefGoogle Scholar
  28. 28.
    Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. World Federation of Societies of biological psychiatry task force on unipolar depressive disorders. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–85.PubMedCrossRefGoogle Scholar
  29. 29.
    National Institute For Health and Clinical Excellence (NICE). The treatment and management of depression in adults (updated edition)—National Clinical Practice Guideline. 2010. http://www.nice.org.uk/nicemedia/live/12329/45896/45896.pdf. 2018. Accessed 22 Jan 2019
  30. 30.
    Royal Australian and New Zealand College of Psychiatrists (RANZCP). Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry. 2004;38:389–407.CrossRefGoogle Scholar
  31. 31.
    Dutch National Steering Committee Multidisciplinary Guideline Development Mental Health (DNSC). Multidisciplinary Guideline Depression. 2005.Google Scholar
  32. 32.
    •• Smith K. The best drug treatment for psychotic depression: antidepressants, antipsychotics or both combined? BJ Psych Advances. 2017;23:3–8 Excellent review of current evidenced based treatments.CrossRefGoogle Scholar
  33. 33.
    Wijkstra J, Lijmer J, Burger H, Cipriani A, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2015;2015(7):1–65.Google Scholar
  34. 34.
    Wijkstra J, Burger H, van den Broek WW, Birkenhäger TK, Janzing JG, Boks MP, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand. 2010;121:190–200.PubMedCrossRefGoogle Scholar
  35. 35.
    Meyers B, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, et al. STOP-PD group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66:838–47.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Künzel H, Ackl N, Hatzinger M, Held K, Holsboer-Trachsler E, Ising M, et al. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol—a double-blind multicenter trial. J Psychiatr Res. 2009;43:702–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24:365–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Mulsant B, Sweet RA, Rosen J, Pollock BG, Zubenko GS, Flynn T, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001;62:597–604.PubMedCrossRefGoogle Scholar
  39. 39.
    Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990;147: 1203–1208.Google Scholar
  40. 40.
    Spiker D, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142:430–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull. 2013;39(4):787–96.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Tyrka A, Price LH, Mello MF, Mello AF, Carpenter LL. Psychotic major depression: a benefit-risk assessment of treatment options. Drug Saf. 2006;29(6):491–508.PubMedCrossRefGoogle Scholar
  43. 43.
    Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17:244–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Birkenhäger T, Pluijms EM, Lucius SA. ECT response in delusional versus non-delusional depressed inpatients. J Affect Disord. 2003;74:191–5.PubMedCrossRefGoogle Scholar
  45. 45.
    O’Connor M, Knapp R, Husain M, Rummans TA, Petrides G, Smith G, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry. 2001;9(4):382–90.PubMedCrossRefGoogle Scholar
  46. 46.
    Flint A, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry. 2005;13(1):23–8.CrossRefGoogle Scholar
  47. 47.
    Liu A, Rajji TK, Blumberger DM, Daskalakis ZJ, Mulsant BH. Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression. Am J Geriatr Psychiatry. 2014;22(3):216–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Navarro V, Gastó C, Torres X, Masana G, Penadés R, Guarch J, et al. Continuation/maintenance treatment with nortriptyline versus combined nortriptyline and ECT in late-life psychotic depression: a two-year randomized study. Am J Geriatr Psychiatry. 2008;16:498–505.PubMedCrossRefGoogle Scholar
  49. 49.
    Grunhaus L, Dannon PN, Schreiber S, Dolberg OH, Amiaz R, Ziv R, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol Psychiatry. 2000;15(4):314–24.CrossRefGoogle Scholar
  50. 50.
    Martell C, Addis M, Despression in Context JN. Strategies for guided action. New York: Guilford; 2001.Google Scholar
  51. 51.
    Hayes S, Strosahl K, Wilson K. Acceptance and Commitment therapy: the process and practice of mindful change. 2nd ed. New York: Guilford; 2012.Google Scholar
  52. 52.
    Gaudiano B, Nowlan K, Brown LA, Epstein-Lubow G, Miller IW. An open trial of a new acceptance-based behavioral treatment for major depression with psychotic features. Behav Modif. 2013;37:324–55.PubMedCrossRefGoogle Scholar
  53. 53.
    Gaudiano B, Busch AM, Wenze SJ, Nowlan K, Epstein-Lubow G, Miller IW. Acceptance-based behavior therapy for depression with psychosis: results from a pilot feasibility randomized controlled trial. J Psychiatr Pract. 2015;21(5):320–33.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Dolder C, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003;53:1142–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Sackeim H, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation of pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10:96–104.PubMedCrossRefGoogle Scholar
  56. 56.
    Sackeim H, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285:1299–307.PubMedCrossRefGoogle Scholar
  57. 57.
    Aronson T, Shukla S, Hoff A. Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse. Convuls Ther. 1987;3:251–9.PubMedGoogle Scholar
  58. 58.
    Flint A, Rifat SL. Two-year outcome of psychotic depression in late life. Am J Psychiatry. 1998;155:178–83.PubMedGoogle Scholar
  59. 59.
    Murphy E. The prognosis of depression in old age. Br J Psychiatry. 1983;142(2):111–9.PubMedCrossRefGoogle Scholar
  60. 60.
    •• Gournellis R, Tournikioti K, Touloumi G, Thomadakis C, Michalopoulou PG, Michopoulos I, et al. Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. Ann General Psychiatry. 2018;17:39–53 Excellent review of risk of suicide and psychotic depression.CrossRefGoogle Scholar
  61. 61.
    Meyers B, Klimstra SA, Gabriele M, Hamilton M, Kakuma T, Tirumalasetti F, et al. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry. 2001;9:415–22.PubMedCrossRefGoogle Scholar
  62. 62.
    Birkenhäger T, van den Broek WW, Mulder PG, de Lely A. One-year outcome of psychotic depression after successful electroconvulsive therapy. J ECT. 2005;21:221–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Wijkstra J, Burger H, van den Broek WW, Birkenhäger TK, Janzing JG, Boks MP, et al. Long-term response to successful acute pharmacological treatment of psychotic depression. J Affect Disord. 2010;123:238–42.PubMedCrossRefGoogle Scholar
  64. 64.
    Bingham K, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM, Banerjee S, et al. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018;138:267–73.PubMedCrossRefGoogle Scholar
  65. 65.
    Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry. 2003;64:390–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Ribeiro C, Sanacora G, Hoffman R, Ostroff R. The use of ketamine for the treatment of depression in the Context of psychotic symptoms: To the Editor. Biol Psychiatry. 2016;79(9):e65–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Pennybaker S, Luckenbaugh DA, Park LT, Marquardt CA, Zarate CA Jr. Ketamine and psychosis history: antidepressant efficacy and psychotomimetic effects Postinfusion. Biol Psychiatry. 2017;82(5):e35–e6.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Schatzberg A, Rothschild AJ, Langlais PJ, Bird ED, Cole JO. A corticosteroid/dopamine hypothesis for psychotic depression and related states. J Psychiatr Res. 1985;19(1):57–64.PubMedCrossRefGoogle Scholar
  69. 69.
    Belanoff J, Flores BH, Kalezhan M, Sund BB, Schatzberg AF. Rapid reversal of psychotic major depression using mifepristone. J Clin Psychopharmacol. 2001;21:516–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Block T, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biol Psychiatry. 2018;84:46–54.PubMedCrossRefGoogle Scholar
  71. 71.
    Bauer M, Dopfmer S. Lithium augmenatation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19:427–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Price L, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry. 1983;140:318–22.PubMedCrossRefGoogle Scholar
  73. 73.
    Nelson J, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry. 1986;143:363–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Birkenhäger T, van den Broek WW, Wijkstra J, Bruijn JA, van Os E, Boks M, et al. Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression. J Clin Psychopharmacol. 2009;29:513–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;37:222–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Amber R. Thompson
    • 1
  • Aekta Malhotra
    • 1
  • Anthony J. Rothschild
    • 1
    Email author
  1. 1.Department of Psychiatry, Center for Psychopharmacological Research and TreatmentUniversity of Massachusetts Medical School and UMass Memorial HealthcareWorcesterUSA

Personalised recommendations